results. One hundred twelve ICUs reporting 3,228 ICU-months and 550,800 ventilator-days were included. The overall median VAP rate decreased from 5.5 cases (mean, 6.9 cases) per 1,000 ventilator-days at baseline to 0 cases (mean, 3.4 cases) at 16-18 months after implementation ( ) and 0 cases (mean, 2.4 cases) at 28-30 months after implementation ( ). Compared to baseline, VAP P ! .001 P ! .001 rates decreased during all observation periods, with incidence rate ratios of 0.51 (95% confidence interval, 0.41-0.64) at 16-18 months after implementation and 0.29 (95% confidence interval, 0.24-0.34) at 28-30 months after implementation. Compliance with evidencebased therapies increased from 32% at baseline to 75% at 16-18 months after implementation (
) and 84% at 28-30 months after P ! .001 implementation (
). P ! .001 conclusions. A multifaceted intervention was associated with an increased use of evidence-based therapies and a substantial (up to 71%) and sustained (up to 2.5 years) decrease in VAP rates. Ventilator-associated pneumonia (VAP) is a significant and common cause of patient morbidity and mortality, as well as increased healthcare costs. 1 Numerous interventions have independently decreased rates of VAP and the associated adverse outcomes. 2, 3 Nevertheless, a gap exists in the translation of these guidelines into routine clinical practice. 4, 5 Interventions to increase adherence with evidence-based recommendations are paramount to reduce the serious public health consequences associated with VAP. Our objective was to evaluate the impact of a multifaceted intervention on compliance with evidence-based therapies and on VAP rates in a large cohort of adult intensive care units (ICUs) that participated in a statewide quality improvement collaborative.
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methods
Intervention
A multifaceted intervention was implemented to improve adherence to evidence-based practices known to improve care and reduce VAP rates among mechanically ventilated patients. This intervention was part of a statewide quality improvement collaborative involving the Johns Hopkins University Quality and Safety Research Group and the Michigan Health and Hospital Association and known as the Keystone ICU project, as described elsewhere. 6, 7 The Agency for Healthcare Research and Quality (AHRQ) funded the project from October 2003 through September 2005. This study reports data collected during the funding period and for 12 months afterward. Implementation of the intervention and data collection was voluntary, and ICUs did not receive financial support to participate. After the AHRQsponsored period, hospitals paid a fee to the Michigan Health and Hospital Association to participate. As part of the Keystone project, ICUs implemented 4 patient safety interventions starting in March 2004. Two interventions that focused on improving safety culture and communication were implemented first; details of both of these interventions have been published. 8, 9 Two additional interventions that focused on reducing the incidences of catheter-related bloodstream infection (CR-BSI) 7 and VAP were implemented next. Each site decided which intervention to implement first. The implementation period for each intervention was estimated to take 3 months.
In brief, the comprehensive unit-based safety program is a 5-step iterative and validated process to improve safety culture. 9 Before the program began and annually thereafter, a quantitative assessment of the institutional safety culture was performed using a validated survey. 10 A team of frontline staff, which included at least a physician and a nurse, was assembled to implement the program.
Step 1 educated staff on the science of improving patient safety, including systems redesign.
Step 2 asked teams to identify defects (defined as anything clinically or operationally that should not recur).
Step 3 involved "senior executive partnerships" to bridge the gap between management and frontline staff, to help prioritize safety hazards and interventions, and to provide resources to improve safety.
Step 4 asked staff to choose and learn from 1 defect per month, 11, 12 and step 5 asked teams to implement tools (eg, daily goals and morning briefings 8, [13] [14] [15] ) to help improve teamwork and communication. The VAP intervention sought to increase caregivers' use of evidence-based therapies for the prevention of VAP, including the ventilator care bundle. The ventilator care bundle has been an effective strategy to reduce VAP [16] [17] [18] [19] and consists of 5 evidence-based therapies: semirecumbent positioning to decrease the risk of VAP; stress ulcer prophylaxis to decrease gastrointestinal bleeding; prophylaxis to decrease deep venous thrombosis; adjustment of sedation until the patient can follow commands; and daily assessment of readiness to extubate, to reduce the duration of mechanical ventilation. Details regarding the systematic process to select the interventions, convert the interventions into process measures, and evaluate the validity and reliability of the process measures in the ventilator bundle have been published. 16, [20] [21] [22] Our model for organizational change (engage, educate, execute, and evaluate) builds on the existing literature, 23 and the details of our model have been published. 24 A local ICU improvement team was established and included the ICU director and nurse manager, an ICU physician and nurse, and the senior hospital executive. The teams were trained through semimonthly conference calls, coaching by study investigators, and semiannual statewide meetings. Teams were instructed to partner with their local hospital infection preventionist(s) to assist with data collection. Relative to the ventilator bundle, ICU leaders engaged staff by posting their baseline compliance rates for the ventilator care bundle and VAP rates and discussing patients who developed VAP in their unit. To educate teams, study investigators reviewed published guidelines for the prevention of VAP 25 and the evidence to support interventions in the ventilator bundle during conference calls. These guidelines recommended the orotracheal route of intubation, change of ventilator circuits for each new patient and for soiled circuits, use of closed endotracheal suction systems that are changed for each new patient and as clinically indicated, and use of heat and moisture exchangers with weekly changes in the absence of contraindications. The use of subglottic secretion drainage and kinetic beds should be considered. Administration of sucralfates and topical antibiotics to prevent VAP were not recommended. We provided ICU teams with tools (a one-page "fact sheet" summary, a slide set, and references) to educate their staff.
To execute the intervention, teams were instructed to standardize care for ventilated patients and investigate all VAPs by using a structured tool. 11 To standardize, teams were encouraged to modify the "Daily Goals" checklist, 8 which included a section on ventilator care, to meet their needs, and they were also encouraged to complete the form daily for each patient during ICU rounds. Teams were advised to create protocols and standard order sets and to enlist support from clinicians and family members. For example, respiratory therapists were asked to document use of the care bundle in their progress notes, and families were instructed to ask whether patients were receiving the therapies. To evaluate the intervention, teams received their monthly rates of ventilator bundle compliance, number of patients who developed VAP, and quarterly rates of VAP. Teams also received de-identified reports on other participating ICUs to compare performance.
Data Collection: VAP
We relied on trained hospital infection preventionists, who already collect data on the number of VAPs and ventilatordays, and teams obtained this data monthly for the duration of the study. Using infection preventionists minimized the potential for diagnosis bias because they are trained to conduct surveillance for VAP and other healthcare-associated infections by using standardized definitions and methods pro- vided by the CDC in its National Healthcare Safety Network (NHSN). All teams reported use of CDC-NHSN surveillance criteria for pneumonia applied to patients on mechanical ventilators 26 and did not change these criteria throughout the study period. Monthly VAP data for 3-month periods (quarters) were aggregated. The quarterly VAP rate was calculated as the number of infections per 1,000 ventilator-days. Data were assigned to 1 of 12 categories on the basis of implementation of the intervention: at baseline, during the implementation period, or at 1 of 10 three-month intervals occurring up to 30 months after implementation. Teams were instructed to submit at least 3 months of baseline VAP data. Teams were not prevented from implementing the intervention if they did not submit baseline VAP data.
Data Collection: Ventilator Bundle Compliance
Ventilator care bundle compliance was collected by the ICU teams daily by using a cross-sectional sampling strategy and was reported as the proportion of ventilator-days in which patients received each therapy. Explicit definitions for each process measure and associated data collection forms were created (Appendix A). 19 The study investigators trained data collectors through conference calls and face-to-face meetings. We recommended that teams limit the number of data collectors and collect process measures at 1 time point (preferably during morning rounds). After the first quarter of daily data collection, teams were allowed to collect process measures 1-2 days per week (minimum of 15 ventilated patients per month) to minimize burden.
Process and Outcome Measures
The primary outcome was the quarterly VAP rate, which was estimated at baseline and for each of the 12 subsequent quarters. Adherence with the process measures in the ventilator bundle was calculated as the proportion of ventilator-days per quarter in which patients received all 5 therapies.
Statistical Analysis
Median values (with interquartile ranges) and mean values (with standard deviations) were used to summarize the data. A 2-sample Wilcoxon rank-sum test was used to compare median values. Compliance with process measures was compared using the Pearson x 2 test. We hypothesized that the baseline VAP rate would decrease by the end of the 18-month AHRQ-funded implementation period and the reduction would be sustained at 28-30 months after implementation. To explore the relationship between time since implementation of the multifaceted intervention and VAP rates, we used a generalized linear latent and mixed model 27, 28 with a Poisson distribution for the quarterly number of VAPs. In this model, we used robust variance estimation and included 2-level random effects to account for nested clustering within the data. In the model, we adjusted a priori for hospital teaching status (binary variable), hospital size (continuous variable), and ICU type (4 categories). We conducted a sensitivity analysis in which only ICUs with continuous data, including baseline, were included. Reported P values are 2 sided; a P value of .05 or less was considered significant. We used Stata software, version 9.1 (Stata Corp.) 
results
A total of 127 ICUs from 82 hospitals participated at some point in the Keystone ICU project. Of 127 ICUs, 124 submitted VAP data. Of these 124 ICUs, 12 were excluded because teams implemented the intervention after the AHRQfunded period had ended. Thus, 112 ICUs from 72 hospitals, reporting data for 3,228 ICU-months and 550,800 ventilatordays during the entire study period, were included in the final analysis. Table 1 summarizes baseline VAP data overall and according to ICU characteristics. Table 2 shows median VAP rates at baseline and at 2 postimplementation periods. Of 112 participating ICUs, 81 contributed data to the baseline period, 106 to the 16-18-month postimplementation period, and 80 to the 28-30-month postimplementation period. Of 1,232 eligible ICU-quarters (112 ICUs times 11 quarters), data were reported for 1,110 ICUquarters, resulting in 122 ICU-quarters (10%) without complete data. Of 122 quarters, 54 (4%) had missing data, and 68 (6%) had ICUs that stopped submitting data for this project. The overall median VAP rate significantly decreased from 5.5 cases (mean, 6.9 cases) per 1,000 ventilator-days at baseline to 0 cases (mean, 3.4 cases) at 16-18 months after implementation ( ) and 0 cases (mean, 2.4 cases) at 28-P ! .001 30 months after implementation ( ) ( Figure 1 ; Table P ! .001 2). A significant decrease was observed in all ICU subgroups, except hospital size of fewer than 200 beds, for both postimplementation periods. Twelve (15%) ICU-months had no VAP in the baseline period, 203 (67%) in the 16-18-month postimplementation period, and 172 (75%) in the 28-30-month postimplementation period.
The multilevel Poisson regression model demonstrated a significant decrease in VAP rates during all observation periods compared to baseline, with incidence rate ratios of 0.51 (95% confidence interval [CI], 0.41-0.64) at 16-18 months after implementation and 0.29 (95% CI, 0.24-0.34) at 28-30 months after implementation (Table 3) . A sensitivity analysis of data from 57 (51%) of 112 ICUs reporting continuous data from baseline onward demonstrated results similar to those of the primary analysis, with incidence rate ratios of 0.45 (95% CI, 0.31-0.64) at 16-18 months after implementation and 0.28 (95% CI, 0.19-0.41) at 28-30 months after implementation.
Compliance with each of the 5 process measures in the ventilator bundle increased during the study period ( Table  4 ). The composite compliance measure increased from 32% of ventilator-days with compliance at baseline to 75% at 16-18 months after implementation (
) and 84% at 28-P ! .001 30 months after implementation ( ) (Table 4 ; Figure  P 
discussion
This multifaceted intervention was associated with a significant increase in the use of 5 evidence-based therapies for mechanically ventilated patients and a significant and sustained decrease in VAP rates among 112 Michigan ICUs. The overall median rate of VAP decreased to 0 within 18 months of implementation of the intervention. While the median VAP rate was sustained at 0 for another 12 months, the overall mean rate continued to decrease during this period. Over the entire study period, the intervention was associated with a 71% reduction in the VAP rate. Our findings suggest that implementation barriers may exist at larger and academic hospitals. At the 18-month postimplementation mark, ICUs in smaller hospitals demonstrated a larger reduction in VAP rates than did larger hospitals (64% vs 30%), and ICUs in nonteaching hospitals demonstrated a greater reduction in rates compared to teaching hospitals (77% vs 38%). However, these gaps in VAP rates were reduced by the 30-month postimplementation period.
This large-scale project demonstrated significant reductions in VAP rates that were likely the result of translating evidence into practical behaviors and bundling them in a multifaceted quality improvement intervention that also included safety culture and communication improvements. 29, 30 Studies of single hospitals 17, [31] [32] [33] [34] and small multicenter studies 16, [35] [36] [37] [38] have decreased VAP rates by increasing compliance with evidence-based recommendations. Our research builds on these studies by demonstrating that a larger cohort of ICUs can rapidly and significantly reduce VAP rates with a focused multifaceted intervention. Importantly, reductions in VAP rates were sustained for up to 2.5 years.
Evidence supporting the benefit of collaboratives and knowledge translation efforts to improve quality of care is inconsistent. 39 In this project, our change model explicitly incorporated practical strategies for translating evidence into practice. 24 This model focuses on systems of care; engagement of local interdisciplinary teams to assume ownership of the project; centralizing support for technical work, including robust data collection; efforts to improve data quality and reduce missing data; local adaptation of the intervention; for all com-P ! .001 parisons. Patients were excluded from the numerator and denominator if therapies were contraindicated. Contraindications were determined locally and documentation of the contraindication(s) was required in the medical record. culture improvement; and social networking among participating ICUs. 29 The CR-BSI intervention was implemented using the same model and resulted in a large and sustained reduction (up to 66%) in infection rates. 7 Our study has several limitations. First, we did not have a concurrent control group. Consequently, our results may be influenced by temporal changes in VAP rates or patient population, other interventions, or a Hawthorne effect. However, ICU teams would not agree to randomization or delayed implementation. ICUs implemented the intervention at different times, which limited seasonal trends. In addition, no similarly large reduction in VAP rates was observed nationally during this time period. 40 Second, we did not require a uniform surveillance definition for VAP. Nevertheless, all teams reported use of CDC-NHSN surveillance criteria for pneumonia applied to patients on mechanical ventilators, and teams did not change the criteria used throughout the study period. While differences in measuring VAP among hospitals may influence absolute rates of VAP, trends in VAP should be unbiased. In addition, we were not able to determine the precise version of CDC criteria for pneumonia used or to evaluate the reliability with which infection preventionists applied these definitions. This lack of validation would render the absolute rate reductions of VAP less precise, but the relative risks remain sound. We did not have the resources to perform site visits or to ask teams to perform independent audits. Rather, we tapped into the existing infrastructure and used trained hospital-based infection preventionists who collected data on VAP rates independent of this project. The use of trained infection pre-ventionists for collection of VAP is well accepted in both published studies and federally mandated reporting of hospital-associated infections.
Third, we could not evaluate the relative importance of individual therapies in the ventilator bundle because of a high collinearity among process measures. For example, patients that received semirecumbent positioning often received other therapies in the bundle. Also, the bundle was originally aimed at reducing complications associated with mechanical ventilation, not VAP prevention specifically. Thus, only 3 of the 5 therapies (semirecumbent positioning, adjustment of sedation, and daily assessment of readiness for extubation) are currently recommended for the prevention of VAP.
2 While the bundle has been published as an effective strategy for VAP prevention and is advocated by national organizations, there is significant concern about its internal validity. 41 We believe that the bundle should be revised to reflect current recommendations for the prevention of VAP prior to broadscale implementation.
Fourth, we did not evaluate whether patients were receiving other interventions such as oral care or strategies to minimize contamination of the ventilator, which may have contributed to reductions in VAP. Several teams reported that they implemented oral-care protocols as a result of this study. One of the benefits of implementing quality improvement efforts is tailoring the identification and mitigation of risks to the ICU. We chose to measure the interventions in the ventilator bundle because our preliminary work found that patients often failed to receive them. The specific interventions to reduce VAP (eg, circuit changes) typically happened at a unit level. That is, all or no patients received them, and we measured therapies for which there was substantial variation in use.
Fifth, we did not have sufficient resources to evaluate the importance of concomitant Keystone project interventions to improve culture and communication on VAP rates or whether ICUs had preexisting VAP quality improvement teams. Therefore, we cannot state that improvements in compliance with the ventilator bundle were solely responsible for reductions in VAP. In addition, we had insufficient resources to evaluate the impact of our intervention on duration of mechanical ventilation, length of stay, or mortality. Furthermore, it would be misleading to attribute mortality reductions solely to VAP. This multifaceted intervention included efforts to reduce CR-BSI and VAP and to improve safety culture and communication. A study evaluating the impact of the Keystone project on mortality and length of stay has been published. 42 This study suggests that most VAPs are preventable, which has important public health implications. Despite a growing awareness to focus efforts on translating research into practice, evidence of success is sparse; however, we have demonstrated that VAP can be successfully prevented across a large and diverse cohort of ICUs. Our multifaceted VAP intervention was implemented without expensive technology or funding for the participating ICUs. Broad use of this multifaceted intervention could significantly reduce morbidity, mortality, and costs of care attributed to VAP. Furthermore, the Keystone ICU project may be a model for large-scale improvement projects in patient safety and public health. Patient Safety Programme and receives honoraria from various hospitals, agencies, and professional societies. S.E.C. has received support from the Centers for Disease Control and Prevention, AdvanDx, Cubist Pharmaceuticals, and Astellas for unrelated research; is a consultant to Merck; and has been on advisory boards for Rib-X and Forest Laboratories. J.B.S. has received honoraria and travel expenses from the Institute for Healthcare Improvement, the American Medical Association, the National Patient Safety Agency (UK), and various hospitals and hospital associations. J.B.S. also created the Safety Attitudes Questionnaire (SAQ), which was the instrument used to assess safety culture in the current study. He does not receive royalties from the SAQ, and it is available on the Internet for free to researchers and for quality improvement efforts. For those who wish to have an outside company manage their survey administration for technical support and customer service, there is a company that does this, to which J.B.S. licensed the rights of the SAQ. The company is called Pascal Metrics. J.B.S. has permission to act as a paid consultant to Pascal Metrics but has not yet done so. R.H. has consulted for the MHA. P.P. has consulted for Edward Life Sciences and received honoraria and/or travel expenses from Lilly Pharmaceutical and Edward Life Sciences. P.J.P. has received support from private philanthropy, the Society for Cardiovascular Anesthesia Foundation, the World Health Organization, JHPIEGO, and the National Patient Safety Agency (UK) for unrelated research; has received honoraria and travel expenses from various hospitals and through the Speakers' Bureau; and receives royalties from his book Safe Patients Smart Hospitals. Percentage of ventilator-days on which the patient received any stress ulcer prophylaxis. Stress ulcer prophylaxis is defined as the use of any of the following drugs: H2 antagonists, proton pump inhibitors, sucralfates, or antacids. To meet the intent of this measure, the use of these drugs is not dose or regimen dependent.
Deep venous thrombosis prophylaxis
Percentage of ventilator-days on which the patient received any deep venous thrombosis prophylaxis. Deep venous thrombosis prophylaxis is defined as the use of any of the following drugs: low-dose unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, or warfarin. To meet the intent of this measure, the use of these drugs is not dose or regimen dependent. Therapeutic anticoagulation would meet (and exceed) the requirements for this measure.
Followed commands
Percentage of ventilator-days on which patients followed commands, at least once during the day if patients had received any sedation. Sedation is defined as the use of any of the following drugs: lorazepam, midazolam, propofol, fentanyl, morphine, meperidine, hydromorphone, or Haldol, within the past 24 hours. Assessment of ability to extubate
Percentage of ventilator-days on which patients were evaluated with a rapid-shallow breathing index or trial of spontaneous ventilation. A rapid-shallow breathing index is calculated as respiratory frequency divided by tidal volume, in liters. A trial of spontaneous breathing is defined as a period of time where ventilatory support is removed and the patient is allowed to breathe through either a T-tube circuit or a ventilatory circuit by using "flow triggering" (rather than triggering by pressure) with a continuous positive airway pressure of 5 cm of water.
note. Patients were excluded from the numerator and denominator if therapies were contraindicated. Contraindications were determined locally, and documentation of the contraindications was required in the medical record. 19 appendix b hospitals participating in mha keystone icu project vap intervention
